ABOUT ANTENGENE MANAGEMENT TEAM SCIENTIFIC ADVISORY BOARD BOARD OF DIRECTORS INVESTORS

SCIENTIFIC ADVISORY BOARD

Jeffrey Barrett, Ph.D.

Senior Advisor, Quantitative Medicine, Critical Path Institute

Dr. Barrett is Senior Advisor, Quantitative Medicine, Critical Path Institute. Prior to that Dr. Barrett was Head of Quantitative Sciences at Bill & Melinda Gates Medical Research Institute. He also served as Vice President at Sanofi as Global Head of Translational Informatics, Pediatric Clinical Pharmacology, and Interdisciplinary Pharmacometrics Program (IPP). He was professor of Pediatrics at The Children's Hospital of Philadelphia & the University of Pennsylvania. Prior to Bill & Melinda Gates Medical Research Institute, Dr. Jeffrey S. Barrett worked at several leading pharmaceuticals companies or laboratories including Sanofi Pharmaceuticals, Aventis Pharmaceuticals, DuPont Pharmaceuticals Company, Somerset Pharmaceuticals and Merck Research Laboratories. He received his Ph.D. in Pharmacokinetics from University of Michigan.

Joseph Camardo, M.D.

Head of Medical Affairs, ADC Therapeutics
Former Senior Vice President of Celgene Global Health and Global Medical Affairs, Celgene

Dr. Joseph Camardo serves as Head of Medical Affairs, ADC Therapeutics. Prior to joining ADC Therapeutics, Dr. Camardo was Senior Vice President-Global Medical Affairs and Global Health at Celgene Corp. Dr. Camardo is also on the Board of Directors at ScripsAmerica, Inc., Mali Health Organizing Project and Rosemont College. Prior to Celgene, Dr. Camardo served at several leading pharmaceutical companies, including Forest Laboratories, Pfizer and Wyeth, where he held senior positions in Medical Affairs. He received his B.A. with a major in Biology from the University of Pennsylvania, and a doctorate in Internal Medicine from The Perelman School of Medicine, University of Pennsylvania. He is a Member of American College of Physicians Foundation.

Robert Gale, M.D.

Chief Editor of Leukemia, Visiting Professor of Imperial College London
Former Executive Director of Clinical Research and Development, Celgene

Dr. Gale is a physician and medical researcher, he received a Ph.D. in microbiology and immunology from the University of California, Los Angeles. His areas of research include leukemia and other bone marrow disorders. He is an expert in leukemia biology, etiology/causation and therapy, bone marrow transplantation, lymphoma and multiple myeloma. Dr. Gale was on the faculty of UCLA, is currently on the Medical Staff and is Visiting Professor of Haematology at the Imperial College London. He has published over 800 scientific articles and more than 20 books, mostly on Leukemia, transplantation,cancer immunology and radiation. He was Executive Director of Clinical Research and Development, hematology and oncology at Celgene.

Shaji Kumar, M.D.

Chair, Myeloma, Amyloid, and Dysproteinemia DOG, Mayo Clinic Cancer Center
Medical Director, Cancer Center Clinical Research, Mayo Medical Center

Dr. Shaji Kumar is currently Chair of Myeloma, Amyloid, and Dysproteinemia DOG and Medical Director of Cancer Center Clinical Research at Mayo Clinic. Dr. Kumar is Chair of American Society of Hematology and holds membership in several professional organizations including American Society of Clinical Oncology, American Association for Cancer Research, American Society of Blood and Marrow Transplantation and European Hematology Association. He has published numerous articles, abstracts, editorials, and letters in peer-reviewed journals, including Blood, Journal of Clinical Oncology, Leukemia, American Journal of Hematology, British Journal of Haematology, and Bone Marrow Transplantation. He is also member of the editorial board for several journals including American Journal of Hematology, European Journal of Clinical and Medical Oncology and Leukemia.

Thierry Facon, M.D.

Professor, Department of Hematology, Lille University Hospital, University of Lille

Dr. Thierry Facon, is Head of the Haematology Department since 2010 and Head of Division (Haematology, Medical Oncology, Infectious diseases, Internal Medicine) since 2014 at Lille University Hospital, France. He received his MD at Lille University School of Medicine in 1987 and became Assistant Professor of Hematology at Lille University Hospital in 1989.

Professor Facon was President of the Intergroupe Francophone du Myélome (IFM) between 2003 and 2006, Vice-President of the French Society of Hematology between 2005 and 2013. He is a member of the American Society of Hematology (ASH), the International Myeloma Working Group (IMWG), the International Myeloma Foundation (IMF). He serves currently as Associate Editor of Leukemia, and is a founder member and administrator of the Fondation Française pour la Recherche contre le Myélome et les Gammapathies (FFRMG) under the aegis of the Fondation de France. He is a co-organizer of the myeloma international COMY meeting and a member of the ESH board. Professor Facon is author and co-author of a number of articles and has published his work in various prestigious international journals including, as first or senior author, The Lancet and The New England Journal of Medicine.

Timothy Block, Ph.D.

Co- Founder and President, Baruch S. Blumberg Institute and Hepatitis B Foundation

Dr. Timothy Block is Co- Founder and President of Baruch S. Blumberg Institute and Hepatitis B Foundation, which established the Institute in 2003 to advance its research mission to find a cure for hepatitis B. He has been involved in hepatitis research for more than 25 years and is internationally recognized for his scholarship and scientific contributions to the field. Dr. Block was a tenured Professor at Thomas Jefferson University for 20 years and at Drexel University College of Medicine for 10 years.

Andrew Zhu,M.D., Ph.D.

Director, Liver cancer research, Massachusetts General Hospital Cancer Center

Dr. Andrew X. Zhu is Professor of Medicine at Harvard Medical School and Director of Liver Cancer Research at Massachusetts General Hospital Cancer Center. The major focus of his research is to develop more effective therapies for hepatocellular carcinoma (HCC) and cholangiocarcinoma through phase I, II and III clinical trials. The second area of his research interests is directed at the development of novel circulating and imaging biomarkers for targeted therapeutics that have prognostic and/or predictive significance. The third area of his research is to define and characterize known or novel genetic mutations in HCC and cholangiocarcinoma and assess their potential correlation with clinical outcomes and as therapeutic targets.

As a widely published author, Dr. Zhu has served as a principle investigator in many clinical trials in HCC, cholangiocarcinoma and other gastrointestinal cancers. He is the invited reviewer for many medical journals and has lectured extensively on HCC and other gastrointestinal cancers. An internationally recognized leader in HCC and cholangiocarcinoma, he has led early efforts of developing several molecularly targeted agents in liver cancers and studying the predictive and surrogate circulating and imaging biomarkers. He is a founding board member of the International Liver Cancer Association, Fellow of American College of Physicians, and a member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research. Dr. Zhu serves on the Hepatobiliary Cancer committee of the National Comprehensive Cancer Network, the Grants Selection Committee of ASCO, and the Hepatobiliary Cancer Task Force of The NCI Gastrointestinal Cancer Steering Committee (GISC). He has received several awards for his work, including V Foundation Translational Research Award, Lorenzo Cappussotti Award, and Jonathan Kraft Translational Award.